Filtered By:
Condition: Atrial Fibrillation
Procedure: Dialysis
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 370 results found since Jan 2013.
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood
AbstractDabigatran etexilate is an oral direct thrombin (Factor IIa) inhibitor approved for patients with atrial fibrillation and for management of risk of deep vein thrombosis and pulmonary embolism. Dabigatran offers advantages over treatment with warfarin, including limited laboratory monitoring. It is equivalent in prevention of stroke and deep vein thrombosis with essentially equivalent complication rates. In contrast to warfarin, reversal of the anticoagulation is less well established. Idarucizumab is available for reversal, however supporting research is mixed; the agent also happens to be quite expensive making av...
Source: Indian Journal of Hematology and Blood Transfusion - June 21, 2020 Category: Hematology Source Type: research
Device use for proximal anastomosis on ascending aorta in off-pump coronary artery bypass grafting.
CONCLUSIONS: Clinical safety of Device use in CABG comparable to No-touch for mortality and morbidity. Hemostasis may be a key issue for accomplishing higher level quality control when devices used in proximal anastomosis of CABG.
PMID: 33065052 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - October 13, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Saito A, Kumamaru H, Miyata H, Motomura N Tags: Ann Thorac Surg Source Type: research
Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis
ConclusionsDOACs did not provide benefit over warfarin regarding effectiveness and safety in AF patients undergoing dialysis. The use of OAC was not associated with a lower risk of IS/SE in ESRD AF patients when compared to those without OAC use.
Source: Cardiovascular Drugs and Therapy - November 19, 2020 Category: Cardiology Source Type: research
Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4 –5 Chronic Kidney Disease or on Dialysis
ConclusionsCurrent evidence suggests that rivaroxaban or apixaban are safe and at least as effective as warfarin in patients with AF and stage 4 –5 CKD or on dialysis.
Source: Cardiovascular Drugs and Therapy - February 4, 2021 Category: Cardiology Source Type: research
Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial
CONCLUSIONS: Ramipril did not reduce the risk of major cardiovascular events in patients on maintenance hemodialysis.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ARCADIA, NCT00985322 and European Union Drug Regulating Authorities Clinical Trials Database number 2008-003529-17.PMID:33782036 | DOI:10.2215/CJN.12940820
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 30, 2021 Category: Urology & Nephrology Authors: Piero Ruggenenti Manuel Alfredo Podest à Matias Trillini Annalisa Perna Tobia Peracchi Nadia Rubis Davide Villa Davide Martinetti Monica Cortinovis Patrizia Ondei Carmela Giuseppina Condemi Carlo Maria Guastoni Agnese Meterangelis Antonio Granata Emanuel Source Type: research
Prior ischemic strokes are non-inferior for predicting future ischemic strokes than CHA2DS2-VASc score in hemodialysis patients with non-valvular atrial fibrillation
We tested whether CHA2DS2-VASc and/or HAS-BLED scores better predict ischemic stroke and major bleeding, respectively, than their individual components in maintenance hemodialysis (MHD) patients with atrial fibri...
Source: BMC Nephrology - May 15, 2021 Category: Urology & Nephrology Authors: Anat Bel-Ange, Shani Zilberman Itskovich, Liana Avivi, Kobi Stav, Shai Efrati and Ilia Beberashvili Tags: Research Source Type: research
Anticoagulation in special patient populations with atrial fibrillation
Herz. 2021 Jul 5. doi: 10.1007/s00059-021-05042-1. Online ahead of print.ABSTRACTAnticoagulation in patients with atrial fibrillation (AF) should be guided by considerations of the risk of thromboembolism, stroke, and bleeding as well as the patient's preference. Well-recognized scores have been developed to help the clinician in daily risk assessment, but there are several special patient populations for whom scores are not developed or validated. Furthermore, these patients were not adequately represented in the pivotal randomized trials for non-vitamin K antagonist oral anticoagulants (NOACs). In patients with cancer, t...
Source: Herz - July 5, 2021 Category: Cardiology Authors: Laura Ueberham Gerhard Hindricks Source Type: research
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
